HBL
MCID: HPT022
MIFTS: 55

Hepatoblastoma (HBL) malady

Categories: Rare diseases, Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Hepatoblastoma

Aliases & Descriptions for Hepatoblastoma:

Name: Hepatoblastoma 12 50 29 52 42 14 69
Hbl 12

Classifications:



External Ids:

Disease Ontology 12 DOID:687
ICD10 33 C22.2
MeSH 42 D018197
NCIt 47 C3728
SNOMED-CT 64 109843000 45024009
UMLS 69 C0206624

Summaries for Hepatoblastoma

NIH Rare Diseases : 50 hepatoblastoma is a rare malignant (cancerous) tumor of the liver that usually occurs in the first 3 years of life. in early stages of the condition, there may be no concerning signs or symptoms. as the tumor gets larger, affected children may experience a painful, abdominal lump; swelling of the abdomen; unexplained weight loss; loss of appetite; and/or nausea and vomiting. the exact underlying cause of hepatoblastoma is poorly understood. risk factors for the tumor include prematurity with a very low birth weight, early exposure to hepatitis b infection, biliary atresia, and several different genetic conditions (i.e. beckwith-wiedemann syndrome, familial adenomatous polyposis, aicardi syndrome, glycogen storage disease, and simpson-golabi-behmel syndrome). treatment varies based on the severity of the condition but may include a combination of surgery, watchful waiting, chemotherapy, and/or radiation therapy. last updated: 1/20/2016

MalaCards based summary : Hepatoblastoma, also known as hbl, is related to mixed hepatoblastoma and hepatocellular carcinoma, and has symptoms including icterus An important gene associated with Hepatoblastoma is CDO1 (Cysteine Dioxygenase Type 1), and among its related pathways/superpathways are Apoptosis Modulation and Signaling and Development HGF signaling pathway. The drugs Lenograstim and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include liver, fetal liver and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cellular

Wikipedia : 71 Hepatoblastoma is an uncommon malignant liver cancer occurring in infants and children and composed of... more...

Related Diseases for Hepatoblastoma

Diseases related to Hepatoblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
id Related Disease Score Top Affiliating Genes
1 mixed hepatoblastoma 12.0
2 hepatocellular carcinoma 12.0
3 macrotrabecular hepatoblastoma 11.8
4 beckwith-wiedemann syndrome 11.2
5 hypobetalipoproteinemia, familial, 2 11.1
6 ehlers-danlos/osteogenesis imperfecta syndrome 10.3 H19 IGF2
7 toxin-mediated infectious botulism 10.3 H19 IGF2
8 macular degeneration, early-onset 10.3 APC CTNNB1
9 hall-riggs mental retardation syndrome 10.3 H19 IGF2
10 epibulbar lipodermoid-preauricular appendage-polythelia syndrome 10.3 H19 IGF2
11 inclusion-cell disease 10.3 APC H19 IGF2
12 submucosal invasive colon adenocarcinoma 10.2 AFP APC CTNNB1 IGF2
13 hepatitis 10.2
14 adult myxoid chondrosarcoma 10.2 CTNNB1 KRT7
15 nebulin-related early-onset distal myopathy 10.2 CDKN1C IGF2
16 eccrine papillary adenoma 10.2 AFP KRT7
17 fetal warfarin syndrome 10.2 APOA1 H19 IGF2
18 neonatal urinary tract infectious disease 10.2 BCL2L1 CASP3
19 medullomyoblastoma 10.1 AFP GPC3 KRT7
20 retroperitoneal hemangiopericytoma 10.1 AFP GPC3 KRT7
21 advanced sleep phase syndrome 10.1 CTNNB1 KRT7 PLAG1
22 hair follicle neoplasm 10.1 AFP GPC3 KRT7
23 hemorrhagic fever 10.1 CDKN1C H19 IGF2
24 focal epithelial hyperplasia 10.1 AFP APOA1 GPC3
25 dental abscess 10.1 CDKN1C H19 IGF2
26 basophilic carcinoma 10.1 AFP GPC3 KRT7
27 gastrointestinal neuroendocrine tumor 10.1 IGF2 KRT7
28 nodular cutaneous amyloidosis 10.1 BIRC5 CTNNB1 KRT7
29 endocrine organ benign neoplasm 10.1 CTNNB1 KRT7 PLAG1
30 nevoid hypermelanosis, linear and whorled 10.1 ABCB1 BIRC5 CASP3 CTNNB1
31 gastroesophageal junction adenocarcinoma 10.1 AFP CTNNB1 GPC3 KRT7
32 systemic lupus erythematosus with nephritis 3 10.1 ABCB1 SLC22A18
33 malignant pleural solitary fibrous tumor 10.1 AFP CASP3 CTNNB1 KRT7
34 odontotrichoungual-digital-palmar syndrome 10.0 AFP GPC3 KRT7
35 hypotrichosis 8 10.0 ABCB1 CASP3 CYCS IGF2
36 bladder colonic type adenocarcinoma 10.0 APC CTNNB1 KRT7 PLAG1
37 ovarian mucinous adenocarcinoma 10.0 ABCB1 CASP3 CYCS
38 familial adenomatous polyposis 10.0
39 argininosuccinic aciduria 10.0 CDKN1C H19 IGF2
40 diabetes mellitus, noninsulin-dependent, 2 10.0 AFP APC CTNNB1 GPC3 HNF1A
41 toxascariasis 10.0 AFP CDKN1C KRT7
42 neuroblastoma 9.9
43 basal cell nevus syndrome 9.9 APC BCL2L1 CASP3 CTNNB1 HGF IGF2
44 hepatitis b 9.9
45 proctitis 9.9 AFP CASP3 CTNNB1 GPC3 IGF2 KRT7
46 vestibular gland benign neoplasm 9.9 CTNNB1 KRT7 PLAG1
47 leukemia 9.8
48 hemihypertrophy 9.8
49 simpson-golabi-behmel syndrome 9.7
50 adenocarcinoma 9.7

Graphical network of the top 20 diseases related to Hepatoblastoma:



Diseases related to Hepatoblastoma

Symptoms & Phenotypes for Hepatoblastoma

UMLS symptoms related to Hepatoblastoma:


icterus

GenomeRNAi Phenotypes related to Hepatoblastoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.96 CTNNB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.96 CTNNB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.96 AFP
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.96 IGF2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.96 AFP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.96 IGF2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.96 APC
8 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.96 KRT7
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.96 IGF2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.96 IGF2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.96 APC CTNNB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.96 APC KRT7 AFP
13 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.96 CTNNB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.96 APC
15 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.96 APC AFP
16 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.96 CTNNB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.96 APC CTNNB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.96 IGF2 AFP
19 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.96 CTNNB1 IGF2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.96 CTNNB1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.96 CTNNB1 KRT7 IGF2 APC
22 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.96 CTNNB1 IGF2

MGI Mouse Phenotypes related to Hepatoblastoma:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.34 CASP3 CTNNB1 CYCS GPC3 HGF HNF1A
2 cardiovascular system MP:0005385 10.28 CTNNB1 CYCS GPC3 HGF IGF2 PPARA
3 endocrine/exocrine gland MP:0005379 10.27 CTNNB1 CYCS HNF1A IGF2 PLAG1 ABCB1
4 growth/size/body region MP:0005378 10.25 ABCB1 APC BCL2L1 CASP3 CDO1 CTNNB1
5 homeostasis/metabolism MP:0005376 10.25 HNF1A IGF2 KRT7 PPARA ABCB1 AFP
6 mortality/aging MP:0010768 10.1 GPC3 HGF HNF1A IGF2 PPARA ABCB1
7 embryo MP:0005380 10.08 BIRC5 CTNNB1 CYCS GPC3 HGF IGF2
8 craniofacial MP:0005382 10.05 APC CASP3 CDO1 CTNNB1 CYCS GPC3
9 digestive/alimentary MP:0005381 10.04 ABCB1 APC CASP3 CTNNB1 GPC3 HNF1A
10 integument MP:0010771 10.02 APC APOA1 BCL2L1 CASP3 CTNNB1 GPC3
11 liver/biliary system MP:0005370 9.97 ABCB1 AFP APC APOA1 CTNNB1 HGF
12 no phenotypic analysis MP:0003012 9.7 ABCB1 APC CASP3 CTNNB1 HGF HNF1A
13 renal/urinary system MP:0005367 9.5 APC CASP3 CTNNB1 GPC3 HNF1A IGF2
14 reproductive system MP:0005389 9.36 ABCB1 AFP APC BCL2L1 CASP3 CDO1

Drugs & Therapeutics for Hepatoblastoma

Drugs for Hepatoblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved Phase 4,Phase 1 135968-09-1
2
Nicotine Approved Phase 4 54-11-5 942 89594
3 Adjuvants, Immunologic Phase 4,Phase 1
4
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
5
Etoposide Approved Phase 3,Phase 1,Phase 2 33419-42-0 36462
6
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
7
Irinotecan Approved, Investigational Phase 3,Phase 2 97682-44-5, 100286-90-6 60838
8
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
9 Sodium thiosulfate Approved Phase 3
10
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
11
Oxaliplatin Approved, Investigational Phase 3,Phase 2 61825-94-3 5310940 9887054 6857599, 9887054 43805
12
Amifostine Approved, Investigational Phase 3,Phase 1 20537-88-6 2141
13
Fluorouracil Approved Phase 3 51-21-8 3385
14
Succinylcholine Approved Phase 3 306-40-1 5314
15
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
16
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
17
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
18
Gemcitabine Approved Phase 3 95058-81-4 60750
19
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
20
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
21
Cyproheptadine Approved Phase 3 129-03-3 2913
22
Camptothecin Experimental Phase 3,Phase 2 7689-03-4
23
Doxil Approved June 1999 Phase 3,Phase 2 31703
24 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
25 Chelating Agents Phase 3
26 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
27 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
28 Etoposide phosphate Phase 3,Phase 1,Phase 2
29 Anti-Infective Agents Phase 3,Phase 2,Phase 1
30 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
31 Protective Agents Phase 3,Phase 1
32 Antidotes Phase 3
33 Liver Extracts Phase 3,Phase 2,Phase 1
34 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
35 Antitubercular Agents Phase 3
36 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
37 Antioxidants Phase 3
38 Radiation-Protective Agents Phase 3,Phase 1
39 Antimetabolites Phase 3,Phase 1
40 Antimetabolites, Antineoplastic Phase 3
41 Antimitotic Agents Phase 3
42 Neuromuscular Agents Phase 3
43 Neuromuscular Blocking Agents Phase 3
44 Neuromuscular Depolarizing Agents Phase 3
45 Hematinics Phase 3
46 Peripheral Nervous System Agents Phase 3
47 Antifungal Agents Phase 3,Phase 2,Phase 1
48 Protein Kinase Inhibitors Phase 3
49 Antiviral Agents Phase 3
50
Histamine Phosphate Phase 3 51-74-1 65513

Interventional clinical trials:

(show all 36)
id Name Status NCT ID Phase
1 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
2 Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, Stage II, or Stage III Childhood Liver Cancer Unknown status NCT00652132 Phase 3
3 Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer Completed NCT00003994 Phase 3
4 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3
5 Chemotherapy in Treating Children With Liver Cancer Completed NCT00003912 Phase 3
6 Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Recruiting NCT00980460 Phase 3
7 Paediatric Hepatic International Tumour Trial Not yet recruiting NCT03017326 Phase 3
8 Study to Assess Safety and Efficacy of ELAD in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure Terminated NCT01829347 Phase 3
9 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
10 Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma Unknown status NCT00287976 Phase 2
11 Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma Unknown status NCT00077389 Phase 2
12 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2
13 A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Completed NCT01125800 Phase 1, Phase 2
14 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
15 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2
16 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2
17 Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Recruiting NCT01956669 Phase 2
18 A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors Recruiting NCT01804634 Phase 2
19 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Active, not recruiting NCT01154816 Phase 2
20 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Not yet recruiting NCT02867592 Phase 2
21 Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors Withdrawn NCT02011126 Phase 2
22 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Unknown status NCT00007813 Phase 1
23 Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Recruiting NCT02390843 Phase 1
24 Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting NCT01331135 Phase 1
25 Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Terminated NCT00003926 Phase 1
26 MT2004-30: Tomotherapy for Solid Tumors Terminated NCT00623077 Phase 1
27 Cancer and Hearing Loss Related in Children Unknown status NCT02425397
28 Biomarkers in Tissue Samples From Young Patients With Liver Cancer Completed NCT01336881
29 Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer Completed NCT01353300
30 Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer Completed NCT00002485
31 Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience Recruiting NCT02557750
32 Understanding Communication in Healthcare to Achieve Trust (U-CHAT) Recruiting NCT02846038
33 Auto Transplant for High Risk or Relapsed Solid or CNS Tumors Recruiting NCT01505569
34 Collecting and Storing Tissue From Young Patients With Cancer Recruiting NCT00898755
35 Hepatoblastoma Biology Study and Tissue Bank Withdrawn NCT00228683
36 Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors Withdrawn NCT00624962

Search NIH Clinical Center for Hepatoblastoma

Cochrane evidence based reviews: hepatoblastoma

Genetic Tests for Hepatoblastoma

Genetic tests related to Hepatoblastoma:

id Genetic test Affiliating Genes
1 Hepatoblastoma 29

Anatomical Context for Hepatoblastoma

MalaCards organs/tissues related to Hepatoblastoma:

39
Liver, Fetal Liver, Lung, Brain, Heart, Kidney, B Cells

Publications for Hepatoblastoma

Articles related to Hepatoblastoma:

(show top 50) (show all 797)
id Title Authors Year
1
Downregulation of transcription factor GATA4 sensitizes human hepatoblastoma cells to doxorubicin-induced apoptosis. ( 28349834 )
2017
2
Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. ( 27775819 )
2017
3
Multidisciplinary management of hepatoblastoma in children: Experience from a developing country. ( 27781375 )
2017
4
Surgical treatment of childhood hepatoblastoma in the Netherlands (1990-2013). ( 27730288 )
2017
5
Hepatoblastoma in an 11-year-old: Case report and a review of the literature. ( 28079820 )
2017
6
Serum alpha-fetoprotein screening for hepatoblastoma in Beckwith-Wiedemann syndrome. ( 28211991 )
2017
7
Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. ( 27884679 )
2017
8
A common global risk stratification system for hepatoblastoma. ( 27884678 )
2017
9
Fine needle aspiration in the diagnosis and classification of hepatoblastoma: Analysis of 21 New Cases. ( 27933740 )
2017
10
Therapeutic Innovations for Targeting Hepatoblastoma. ( 27793881 )
2016
11
Hepatoblastoma in childhood, long term survival achieved: 2 case reports and literature review. ( 26942331 )
2016
12
NOVEL ADVANCES IN UNDERSTANDING OF MOLECULAR PATHOGENESIS OF HEPATOBLASTOMA: A WNT/BETA-CATENIN PERSPECTIVE! ( 27938502 )
2016
13
Hepatoblastoma modeling in mice places Nrf2 within a cancer field established by mutant I^-catenin. ( 27734029 )
2016
14
POST-TEXT III and IV Hepatoblastoma: Extended Hepatic Resection Avoids Liver Transplantation in Selected Cases. ( 27501172 )
2016
15
Hepatoblastoma of the adult with pericardial metastasis: A case report. ( 26826931 )
2016
16
Hepatoblastoma in a mosaic trisomy 18 child with hemihypertrophy. ( 26795740 )
2016
17
Usefulness of three-dimensional(3D) simulation software in hepatectomy for pediatric hepatoblastoma. ( 27566028 )
2016
18
Truncated neurokinin-1 receptor is an ubiquitous antitumor target in hepatoblastoma, and its expression is independent of tumor biology and stage. ( 26870298 )
2016
19
Clinical prognostic value of DNA methylation in hepatoblastoma: Four novel tumor suppressor candidates. ( 26991471 )
2016
20
GATA4 promotes hepatoblastoma cell proliferation by altering expression of miR125b and DKK3. ( 27788486 )
2016
21
Diagnostic and prognostic values of serum exosomal microRNA-21 in children with hepatoblastoma: a Chinese population-based study. ( 27601233 )
2016
22
Corrigendum: First Experience of Ultrasound-guided Percutaneous Ablation for Recurrent Hepatoblastoma after Liver Resection in Children. ( 27632926 )
2016
23
Low expression of N-myc downstream-regulated gene 2 (NDRG2) correlates with poor prognosis in hepatoblastoma. ( 26646663 )
2016
24
FGF19 functions as autocrine growth factor for hepatoblastoma. ( 27382436 )
2016
25
Nine-Year Follow-up in a Child with Antenatally Diagnosed Hepatoblastoma. ( 27277663 )
2016
26
11C-Acetate Positron Emission Tomography for Detection of Occult Metastatic Recurrence in Hepatoblastoma. ( 26907645 )
2016
27
Adult hepatoblastoma: a review of 47 cases. ( 27905197 )
2016
28
Genetic Counselor Practices Involving Pediatric Patients with FAP: an Investigation of their Self-Reported Strategies for Genetic Testing and Hepatoblastoma Screening. ( 27913912 )
2016
29
Hepatoblastoma: A Need for Cell Lines and Tissue Banks to Develop Targeted Drug Therapies. ( 27047905 )
2016
30
Hepatoblastoma of the adult: A systematic review of the literature. ( 27566042 )
2016
31
Benefit of early inflow exclusion during living donor liver transplantation for unresectable hepatoblastoma. ( 27325360 )
2016
32
Targeting Aurora A kinase with Alisertib (ALS) Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Hepatoblastoma HepG2 Cells. ( 27396604 )
2016
33
Effects of an early referral system on liver transplantation for hepatoblastoma at Texas Children's Hospital. ( 27018238 )
2016
34
Chemotherapy-induced B-cell depletion in hepatoblastoma patients undergoing ABO-incompatible living donor liver transplantation. ( 27012966 )
2016
35
Loss of EGFR-ASAP1 signaling in metastatic and unresectable hepatoblastoma. ( 27910913 )
2016
36
Hepatoblastoma Arising in a Pigmented I^-catenin-activated Hepatocellular Adenoma: Case Report and Review of the Literature. ( 27096257 )
2016
37
Cerebral Metastasis of Hepatoblastoma: A Review. ( 27111454 )
2016
38
Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma. ( 27635950 )
2016
39
Early multifocal recurrence of hepatoblastoma in the residual liver after R0 liver resection with ALPPS procedure: a case report. ( 27826578 )
2016
40
Involvement of PI3K/Akt, ERK and p38 signaling pathways in emodin-mediated extrinsic and intrinsic human hepatoblastoma cell apoptosis. ( 27032576 )
2016
41
Enhancer of zeste homolog 2 depletion arrests the proliferation of hepatoblastoma cells. ( 26848027 )
2016
42
Genome-wide analysis of DNA methylation in hepatoblastoma tissues. ( 27446465 )
2016
43
Resectability and tumor response after preoperative chemotherapy in hepatoblastoma treated by the Japanese Study Group for Pediatric Liver Tumor (JPLT)-2 protocol. ( 27712887 )
2016
44
Chronic Myeloid Leukemia and Hepatoblastoma: Two Cancer Models to Link Metabolism to Stem Cells. ( 27148487 )
2016
45
Targeting long non-coding RNA-TUG1 inhibits tumor growth and angiogenesis in hepatoblastoma. ( 27362796 )
2016
46
Chemical characterization of Pleurotus eryngii polysaccharide and its tumor-inhibitory effects against human hepatoblastoma HepG-2 cells. ( 26794745 )
2016
47
Hepatoblastoma in Explanted Livers of Patients With Biliary Atresia. ( 27457778 )
2016
48
Hepatitis B virus X protein mediated suppression of miRNA-122 expression enhances hepatoblastoma cell proliferation through cyclin G1-p53 axis. ( 27528885 )
2016
49
Hepatoblastoma and Abernethy Malformation Type I: Case Report. ( 27467369 )
2016
50
Combined low miR-34s are associated with unfavorable prognosis in children with hepatoblastoma: A Chinese population-based study. ( 27046304 )
2016

Variations for Hepatoblastoma

ClinVar genetic disease variations for Hepatoblastoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 APC NM_000038.5(APC): c.4183A> T (p.Ser1395Cys) single nucleotide variant Pathogenic rs137854578 GRCh37 Chromosome 5, 112175474: 112175474
2 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
3 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097

Copy number variations for Hepatoblastoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 48501 11 1 52900000 Methylation H19 Hepatoblastoma
2 48504 11 1 52900000 Methylation IGF2 Hepatoblastoma

Expression for Hepatoblastoma

Search GEO for disease gene expression data for Hepatoblastoma.

Pathways for Hepatoblastoma

Pathways related to Hepatoblastoma according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.68 BCL2L1 BIRC5 CASP3 CYCS IGF2
2
Show member pathways
12.65 APC BCL2L1 CASP3 CTNNB1 CYCS HGF
3 12.29 APC BIRC5 CTNNB1 HNF1A
4
Show member pathways
12.18 APC BIRC5 CASP3 CTNNB1 CYCS
5 12.12 BCL2L1 BIRC5 CASP3 CYCS
6 12.1 APC BCL2L1 BIRC5 CASP3 CTNNB1 CYCS
7 12.07 CASP3 CTNNB1 GPC3 HGF IGF2
8 12.02 AFP APC BIRC5 CTNNB1
9 11.96 APC BCL2L1 CASP3 CTNNB1
10 11.87 APC BCL2L1 BIRC5 CASP3 CTNNB1
11
Show member pathways
11.63 BCL2L1 BIRC5 CASP3 CYCS
12 11.49 BCL2L1 BIRC5 CASP3 CYCS
13 11.39 APC CTNNB1 HNF1A
14 11.34 AFP APOA1 HNF1A
15 11.17 BCL2L1 CASP3 CYCS
16 11.16 BCL2L1 BIRC5 CASP3 HNF1A
17 11.11 APC CTNNB1 HGF
18 10.65 ABCB1 BCL2L1
19 10.29 ABCB1 BCL2L1 CASP3 CYCS
20 10.1 BCL2L1 CYCS

GO Terms for Hepatoblastoma

Cellular components related to Hepatoblastoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Wnt signalosome GO:1990909 9.16 APC CTNNB1
2 beta-catenin destruction complex GO:0030877 8.96 APC CTNNB1
3 catenin complex GO:0016342 8.62 APC CTNNB1

Biological processes related to Hepatoblastoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.65 BCL2L1 BIRC5 CTNNB1 HGF IGF2
2 negative regulation of inflammatory response GO:0050728 9.33 APOA1 HGF PPARA
3 fatty acid transport GO:0015908 9.32 HNF1A PPARA
4 cellular protein metabolic process GO:0044267 9.26 AFP APOA1 GPC3 IGF2
5 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c GO:0008635 8.62 CASP3 CYCS

Molecular functions related to Hepatoblastoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CASP3 CDKN1C

Sources for Hepatoblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....